Similar articles for PMID: 30244621

Year	Number of Results
2009	1
2010	3
2011	2
2012	4
2013	9
2014	17
2015	6
2016	13
2017	13
2018	8
2019	17
2020	14
2021	8
2022	3
2023	2
2024	0

1

Does Axl have potential as a therapeutic target in pancreatic cancer?

Du W, Brekken RA. Du W, et al. Expert Opin Ther Targets. 2018 Nov;22(11):955-966. doi: 10.1080/14728222.2018.1527315. Epub 2018 Oct 3. Expert Opin Ther Targets. 2018. PMID: 30244621 Free PMC article. Review.

2

AXL Is a Key Factor for Cell Plasticity and Promotes Metastasis in Pancreatic Cancer.

Du W, Phinney NZ, Huang H, Wang Z, Westcott J, Toombs JE, Zhang Y, Beg MS, Wilkie TM, Lorens JB, Brekken RA. Du W, et al. Mol Cancer Res. 2021 Aug;19(8):1412-1421. doi: 10.1158/1541-7786.MCR-20-0860. Epub 2021 Apr 2. Mol Cancer Res. 2021. PMID: 33811159 Free PMC article.

3

MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents.

McDaniel NK, Cummings CT, Iida M, Hülse J, Pearson HE, Vasileiadi E, Parker RE, Orbuch RA, Ondracek OJ, Welke NB, Kang GH, Davies KD, Wang X, Frye SV, Earp HS, Harari PM, Kimple RJ, DeRyckere D, Graham DK, Wheeler DL. McDaniel NK, et al. Mol Cancer Ther. 2018 Nov;17(11):2297-2308. doi: 10.1158/1535-7163.MCT-17-1239. Epub 2018 Aug 9. Mol Cancer Ther. 2018. PMID: 30093568 Free PMC article.

4

Axl inhibitors as novel cancer therapeutic agents.

Shen Y, Chen X, He J, Liao D, Zu X. Shen Y, et al. Life Sci. 2018 Apr 1;198:99-111. doi: 10.1016/j.lfs.2018.02.033. Epub 2018 Feb 27. Life Sci. 2018. PMID: 29496493 Review.

5

Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.

Engelsen AST, Lotsberg ML, Abou Khouzam R, Thiery JP, Lorens JB, Chouaib S, Terry S. Engelsen AST, et al. Front Immunol. 2022 Apr 27;13:869676. doi: 10.3389/fimmu.2022.869676. eCollection 2022. Front Immunol. 2022. PMID: 35572601 Free PMC article. Review.

6

AXL Inhibitor TP-0903 Reduces Metastasis and Therapy Resistance in Pancreatic Cancer.

Zhang Y, Arner EN, Rizvi A, Toombs JE, Huang H, Warner SL, Foulks JM, Brekken RA. Zhang Y, et al. Mol Cancer Ther. 2022 Jan;21(1):38-47. doi: 10.1158/1535-7163.MCT-21-0293. Epub 2021 Oct 21. Mol Cancer Ther. 2022. PMID: 34675118 Free PMC article.

7

TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3Kα inhibition in head and neck squamous cell carcinoma.

Ruicci KM, Meens J, Plantinga P, Stecho W, Pinto N, Yoo J, Fung K, MacNeil D, Mymryk JS, Barrett JW, Howlett CJ, Boutros PC, Ailles L, Nichols AC. Ruicci KM, et al. J Exp Clin Cancer Res. 2020 Oct 15;39(1):217. doi: 10.1186/s13046-020-01713-9. J Exp Clin Cancer Res. 2020. PMID: 33059733 Free PMC article.

8

AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications.

Zhu C, Wei Y, Wei X. Zhu C, et al. Mol Cancer. 2019 Nov 4;18(1):153. doi: 10.1186/s12943-019-1090-3. Mol Cancer. 2019. PMID: 31684958 Free PMC article. Review.

9

Therapeutic Targeting of the Gas6/Axl Signaling Pathway in Cancer.

Tanaka M, Siemann DW. Tanaka M, et al. Int J Mol Sci. 2021 Sep 15;22(18):9953. doi: 10.3390/ijms22189953. Int J Mol Sci. 2021. PMID: 34576116 Free PMC article. Review.

10

Anticancer effect of luteolin is mediated by downregulation of TAM receptor tyrosine kinases, but not interleukin-8, in non-small cell lung cancer cells.

Lee YJ, Lim T, Han MS, Lee SH, Baek SH, Nan HY, Lee C. Lee YJ, et al. Oncol Rep. 2017 Feb;37(2):1219-1226. doi: 10.3892/or.2016.5336. Epub 2016 Dec 23. Oncol Rep. 2017. PMID: 28035396

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

101 results

Results by year